Heart-type fatty acid-binding protein and myocardial creatine kinase enable rapid risk stratification in normotensive patients with pulmonary embolism

Langer, Martin; Forkmann, Mathias; Richter, U; Tausche, Anne‐Kathrin; Sveric, Krunoslav Michael; Christoph, Marian; Ibrahim, Karim; Gunther, Michael F.; Kolschmann, Steffen; Boscheri, Alessandra; Barthel, Peggy; Strasser, Ruth H.; Wunderlich, Carsten

doi:10.1016/j.jcrc.2016.05.014

Cited by 13 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were in line with those of Boscheri et al [6], which reported a negative H-FABP test, in intermediate risk APE patients, as an ideal predictor for low risk of death or complicated in-hospital course (p<0.005). Another study, performed on 161 consecutive hemodynamically stable APE patients, demonstrated a positive H-FABP test as an independent predictor of early mortality, with an OR of 27.1, p=0.001 [23]. These findings have also been confirmed in recent meta-analyses that demonstrated H-FABP as a marker of increased 30-day death or clinical complications risk in non-high-risk APE patients [24][25][26][27].…”

Section: Resultsmentioning

confidence: 65%

Improved Mortality Risk Stratification in Normotensive Patients with Acute Pulmonary Embolism Using Heart-Type Fatty Acid-Binding Protein

2020

Rev.Chim.

View full text Add to dashboard Cite

We performed a prospective, observational study on consecutive non-high-risk patients with APE in order to assess the prognostic value of laboratory markers, including the novel heart-type fatty acid-binding protein (H-FABP), for predicting a composite end point of 30-day mortality or hemodynamic collapse. A total of 61 patients were included and H-FABP was significantly higher in the composite end-point group (9.303 vs. 4.761, p=0.046) and proved to identify more accurately patients at increased risk. Keywords: Pulmonary embolism, heart type fatty acid binding protein, risk assessment

show abstract

Section: Resultsmentioning

confidence: 65%

Improved Mortality Risk Stratification in Normotensive Patients with Acute Pulmonary Embolism Using Heart-Type Fatty Acid-Binding Protein

2020

Rev.Chim.

View full text Add to dashboard Cite

show abstract

“…It is a cytoplasmic protein which was first isolated from ischemic rat hearts in 1988, and was identified as being released from injured myocardium 4 , 5 . Associations between H-FABP and ACS 6 – 8 , acute kidney injury 9 , post-cardiac surgery 10 , acute pulmonary embolism 11 , acute ischemic stroke 12 , severe sepsis 13 , acute heart failure 14 , hypothyroidism 15 and hyperthyroidism 16 have been reported over the past decades. On the other hand, H-FABP has also been used to assess perioperative cardiac risk 17 , 18 .…”

Section: Introductionmentioning

confidence: 99%

The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease

Tseng

et al. 2018

Sci Rep

View full text Add to dashboard Cite

To investigate the prognostic value of heart-type fatty acid binding protein (H-FABP) in patients with stable coronary heart disease (SCHD). A total of 1,071 patients with SCHD were prospectively enrolled in this Taiwan multicenter registry study, followed for 24 months. The cut-off value of H-FABP, 4.143 pg/mL, was determined using receiver operating characteristic curves. The primary cardiovascular (CV) outcome was composite CV events, defined as cardiovascular or cerebrovascular death, myocardial infarction (MI), stroke, angina related-hospitalization, PAOD-related hospitalization and heart failure. Secondary outcomes included CV or cerebrovascular death, nonfatal MI, nonfatal stroke, and acute heart failure-related hospitalization. We found that the high H-FABP group had more than a two-fold higher rate of primary CV outcomes than the low H-FABP group (32.36% vs. 15.78%, p < 0.001). Eleven patients (4.82%) of the high H-FABP group died during the 24 months of follow-up, compared to only one patient (0.12%) in the low H-FABP group. The acute heart failure-related hospitalization rate was also significantly higher in the high H-FABP group (3.5% vs. 0.95%, p < 0.005). The results remained significant after adjusting for baseline covariates. In conclusion, H-FABP was an independent predictor for CV outcomes in the patients with SCHD, mainly in CV death and acute heart failure-related hospitalization.

show abstract

“…Biomarker Changes over Time (Time Dynamics) Non-Cardiac Causes of Altered Levels CK-MB 4-6 h after symptom onset [34,35] Peak occurs after 16-30 h, returns to baseline by 24-36 h [204] Elevated in skeletal muscle injury [205], vigorous exercise [206], stroke [207], trauma patients [208], and kidney disease [209,210]; 1.2-2.6x higher 99th percentile in males [211] and post-operatively in spinal surgery [212] h-FABP 2-4 h after symptom onset [43,44] Peak occurs 6 h after symptom onset, returns to baseline by 24 h [45] Elevated in AKI [213], PE [214], stroke [215], sepsis [216], acute HF [217], NAFLD [218], smoking, and COPD [219] Troponin At presentation and then 2-6 h later if the first result is negative [65] Peak occurs at 12-48 h [220], returns to baseline by 14 days [221] Elevated in sepsis [222], critical illness [223], LVH [224], coronary vasospasm [225], stroke [226], AF [227], heart failure [228], myocarditis [229], dialysis patients [230], males, black people, DM, and HTN [231]; lower in smoking, alcohol use, and statin use [231] sLOX-1 At presentation [96] Peak is maintained from presentation up to 24 h [96] Conflicting association with smoking [95,232]…”

Section: Biomarkermentioning

confidence: 99%

Biomarker Development in Cardiology: Reviewing the Past to Inform the Future

Kott

Bishop

Yang

et al. 2022

Cells

View full text Add to dashboard Cite

Cardiac biomarkers have become pivotal to the clinical practice of cardiology, but there remains much to discover that could benefit cardiology patients. We review the discovery of key protein biomarkers in the fields of acute coronary syndrome, heart failure, and atherosclerosis, giving an overview of the populations they were studied in and the statistics that were used to validate them. We review statistical approaches that are currently in use to assess new biomarkers and overview a framework for biomarker discovery and evaluation that could be incorporated into clinical trials to evaluate cardiovascular outcomes in the future.

show abstract

Heart-type fatty acid-binding protein and myocardial creatine kinase enable rapid risk stratification in normotensive patients with pulmonary embolism

Cited by 13 publications

References 36 publications

Improved Mortality Risk Stratification in Normotensive Patients with Acute Pulmonary Embolism Using Heart-Type Fatty Acid-Binding Protein

Improved Mortality Risk Stratification in Normotensive Patients with Acute Pulmonary Embolism Using Heart-Type Fatty Acid-Binding Protein

The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease

Biomarker Development in Cardiology: Reviewing the Past to Inform the Future

Contact Info

Product

Resources

About